Virtual Influencers earns millions Instagram: up to 353 times more than you - Perhaps by scrolling on Instagram you have come across Miquela, a famous fashion influencer who already has 2.6 million followers. To this day she is so famous that the Times Magazine included her in the list of the 25 Most Influential People on the Internet in 2018.
He is also a singer and his singles on Spotify have already reached 882,000 monthly listeners, among which is a remix called 'Sims' , which has already exceeded 45 million plays.
Like any other influencer, he has photos with other celebrities —like Rosalia -, has worked for major clothing brands like Calvin Klein, has participated in campaigns like Black Lives Matter, and has even attended the most famous festival in the world: Coachella.
The only difference from other content creators? Miquela doesn't exist in reality, she's a virtual influencer.
As surprising as it may seem, virtual influencers are increasingly common on social networks and, especially, on Instagram, according to the Internet World Business magazine.
A new market increasingly profitable for operators, who are already entering millions for them. In fact, the platforms Influencer Marketing Hub and OnBuy have made a calculation of the profits of their developers thanks to the sponsored publications.
"Culturally we are not facing something that is alien to us, it has always been done. We are in the field of entertainment and it's like magic, you like it, you consume it and what you least care about is knowing the trick behind it," explains Franc Carreras, associate professor of digital Marketing at Esade. "It's also ideal for brands”"
Virtual Influencers earns millions Instagram
Miquela charges nothing more and nothing less than 7,211 euros for each sponsored publication, according to the earnings calculator invoices for Instagram Influencers.
This carried over a period of one year means a revenue of 10 million euros from advertising revenue, 353 times more than the average number of workers in Europe, according to OnBuy.
However, it is not the only hyper-realistic robot influencer Of Instagram success, but several companies are launching into the world of likes, to generate money.
The second place in the ranking according to Internet World Business, is occupied by nonoouri, with 363,000 followers, and advertising revenue of 2.5 million euros per year.
Of the 20 hyper-realistic robots on the list, 10 of them charge more than an average European worker.
” They are communication channels that will be maintained because they are much more measurable on the part of companies, " says Gemma Vallet, director of the master of Social Media Branding De La Salle-URL.
Creating robots to the liking of the developer could be a kind of liberation, as they would not have to deal with problems and discussions with celebrities or humans and their demands.
In addition, there are fewer regulations around these, may not refuse to do something, do not suffer from fatigue, when they have to record an announcement can't be wrong, so the process is always much faster, and their creators are not obliged to relieve their identity, giving them a kind of freedom.
The ultimate goal is to attract young people, studying them, and thus creating a kind of engagement with them, so that the robot achieves the greatest possible success.
End of Virtual Influencers earns millions Instagram
The Basque startup that wants to solve a big challenge in the fight against cancer and has raised more than half a million euros in 15 days to start a clinical trial
Immunotherapy was awarded the Nobel Prize in Medicine in 2018 after establishing itself as one of the most promising treatments against cancer, more effective and less toxic than alternatives to treat a disease that is the second leading cause of death in the world.
However, it is not a solution for everyone: between 15% and 45%, depending on the type of cancer of patients receiving this therapy benefit, so it is vital to identify who is likely to be treated with immunotherapy.
"Approximately 25% of lung cases are treated with immunotherapy wrongly," explains Fernando Aguirre, CEO of Fastbase Solutions, to Business Insider Spain.
The company he runs was born to respond precisely to this challenge. It was founded in the Basque Country thanks to the knowledge generated by a group of English and Spanish scientists from the Francis Crick Institute in London and the Biophysics Institute of UPV / EHU and CSIC.
"Fastbase Solutions' technology allows you to see a fabric with resolution levels of 10 nanometers, four times more than the next best technology on the market, " says Aguirre.
This means that the startup is able to see the proteins that any tissue expresses, their modifications and their interactions, not just the quantity, which is the parameter by which current diagnostic methods are usually guided. Basically, the technology makes it possible to determine with high precision which patients will respond to cancer treatment with immunotherapy and which will not.
"The level of information it offers is superior," Aguirre notes. "It allows you to make treatment improvements by stratifying patients," he adds.
So far, the company has found the support of Business angels such as Antonio Parente, founder of Lipotec, and public programs of the Basque country, CDTI and the European Commission.
Immunotherapy is very expensive— around 150,000 euros per patient."and it puts great pressure on health systems," explains Aguirre.
Therefore, if the technology of the startup is able to bring to the market its product 100% effective in identifying patients likely to receive it, it could be a revolution, not only therapeutic, but also economic for hospitals.
The CEO of the startup says that the proof of concept is already done in collaboration with a French hospital and has verified the predictive effectiveness of Fastbase and its superiority over current techniques.
Last year they already managed to register the patent, which is validated for "all major markets", and recently have raised 650,000 euros in an investment round that in record time (15 days) achieved its goal through Capital Cell and is still open today.
The investment will go towards the clinical validation of the technology, which the startup will carry out over the next twelve months with three hospitals in the Basque Country to push this technology to reach clinics and patients.
After this process, the product will have to undergo regulatory approval and the CEO expects to attempt to market the product within 2 years. Looking ahead," the idea is to license it " after passing the entire regulatory process, acknowledges Aguirre.
Fastbase Solutions ' diagnostic solution is not commonly used in hospitals right now, but the CEO dreams that "in a few years this technique will be accepted globally."
In addition, Aguirre expects to have about 5 or 6 trials in progress by then to test the effectiveness of its predictive technology in other types of conditions.
The options are unlimited and go far beyond cancer. The technology could be applied to any type of disease, including infectious diseases, where protein interactions are an important biomarker.
In fact, the startup'S CEO points to its potential for COVID-19 itself, as its technology could be able to observe post-translational protein modifications of the surface of a host cell attacked by a virus, as well as interactions between host cell and virus proteins, and open new avenues for drug and therapy development.